Elagolix 834153-87-6

ʻO ka wehewehe pōkole:

Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
ElagolixCAS:834153-87-6 Endometriosis I-Hale      


Huahana Huahana

Huahana Huahana

NUI HUA

Hoʻohana ʻia kēia lāʻau lapaʻau e nā wahine e kōkua i ka hoʻomaha ʻana i ka ʻeha haʻahaʻa a koʻikoʻi ma muli o kahi maʻi i kapa ʻia ʻo endometriosis.
Hiki ke mālama: Endometriosis
Nā inoa inoa: Orilissa
Papa Laau Laau: LHRH (GnRH) Antagonists
Loaʻa: Pono ka ʻōlelo kuhikuhi
Hāpai: E hōʻalo i ka hoʻohana ʻana i ka wā hāpai
Lactation: E nīnau i ke kauka ma mua o ka hoʻohana ʻana

ʻO Elagolix kahi mea olaola waha, lua-hanauna, non-peptide i hoʻokumu ʻia, pūhui mole liʻiliʻi a me ka gonadotropin-releasing hormone (GnRH; LHRH) receptor antagonist, me ka hana hoʻoneʻe ʻana i ka hormone. Ma ka hoʻoponopono waha, hoʻokūkū ʻo elagolix me GnRH no ka hoʻopaʻa ʻana i ka mea hoʻopaʻa a hoʻopaʻa i ka hōʻailona hōʻailona GnRH i ka pituitary gland anterior. Mālama kēia i ka huna ʻana o ka hormone luteinizing (LH) a me ka follicle stimulating hormone (FSH). I nā kāne, ʻo ka pale ʻana i ka huna LH e pale i ka hoʻokuʻu ʻana o ka testosterone. I nā wahine, ʻo ka pale ʻana i ka FSH a me LH e pale i ka hana ʻana o ka estrogen e nā ovaries. Hiki ke mālama a pale paha i nā hōʻailona o nā maʻi pili i ka hormone sex.

ʻO Elagolix kahi mea kū'ē waha, nonsteroidal gonadotropin hoʻokuʻu i ka hormone (GnRH) e hoʻemi ana i ka hana estrogen a hoʻohana ʻia e mālama i nā ʻano ʻeha o ka endometriosis i nā wahine. Hoʻopili ʻia ka lāʻau ʻo Elagolix me ka haʻahaʻa haʻahaʻa o ka piʻi ʻana o ka enzyme serum i ka wā o ka lāʻau lapaʻau a ʻaʻole naʻe i hoʻopili ʻia i nā manawa o ka hōʻeha ate.

Ua hoʻohana ʻia ʻo Elagolix i nā hoʻokolohua e aʻo ana i ka ʻepekema kumu a me ka mālama ʻana o Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, a me Heavy Menstrual Bleeding. Ma ka 24 Iulai 2018, akā naʻe, ua ʻae ka US Food and Drug Administration (FDA) i ka elagolix o AbbVie ma lalo o ka inoa inoa ʻo Orilissa ma ke ʻano he mea kūʻē mua a me ka waha gonadotropin-releasing hormone (GnRH) antagonist i kūkulu pono ʻia no nā wahine me ka ʻeha endometriosis haʻahaʻa a koʻikoʻi. Ua hoʻoholo ʻia ʻo ka endometriosis kekahi o nā maʻi gynecologic maʻamau ma ʻAmelika Hui Pū ʻIa. ʻO ka mea nui, hōʻike nā manaʻo hoʻokahi i loko o nā wahine he ʻumi o ka makahiki hānau e hoʻopilikia ʻia e ka endometriosis a ʻike i nā hōʻailona hōʻeha ʻeha. Eia kekahi, hiki i nā wahine i loaʻa i kēia maʻi ke pilikia a hiki i ʻeono a ʻumi mau makahiki a kipa aku i nā kauka he nui ma mua o ka loaʻa ʻana o kahi hōʻailona kūpono. Ma hope mai, ʻoiai ua ʻae ʻia ʻo Orilissa (elagolix) e ka FDA ma lalo o ka loiloi mua, ua hāʻawi kēia ʻae wikiwiki hou i nā limahana mālama ola i kahi koho waiwai ʻē aʻe no ka mālama ʻana i nā pono kūpono ʻole o nā wahine i hoʻopilikia ʻia e ka endometriosis, ma muli o ko lākou ʻano kikoʻī a me ka paʻakikī o ka ʻeha endometriosis. .

ʻO ke kinona

dsfs

HOOLAHA ANOAI

Hoʻoponopono maikaʻi1

Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6apono ʻia nā papahana.

Hoʻoponopono maikaʻi2

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Hoʻoponopono maikaʻi3

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Hoʻoponopono maikaʻi4

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kākau inoa ʻana.

HOOLAHA HANA

cpf5
cpf6

Kolea Countec Bottled Packaging Line

cpf7
cpf8

ʻO Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italia CAM Board Packaging Line

cpf11

Mekini Fette Compacting German

cpf12

ʻO Iapana Viswill Tablet ʻIke

cpf14-1

Keena Mana o DCS

HOA

Ka launa pū ʻana o ka honua
Ka launa pū ʻana o ka honua
ʻO ka launa pū ʻana o ka home
ʻO ka launa pū ʻana o ka home

  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou